U.S. Markets closed

Again, Durham pharma loses a drug development partner

Seth Thomas Gulledge
Again, Durham pharma loses a drug development partner

One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.